These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 267509)

  • 1. Potential advances in the clinical use of arabinosyl cytosine.
    Ho DH
    Cancer Treat Rep; 1977 Jul; 61(4):717-22. PubMed ID: 267509
    [No Abstract]   [Full Text] [Related]  

  • 2. Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.
    Heinemann V; Jehn U
    Leukemia; 1990 Nov; 4(11):790-6. PubMed ID: 2232893
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.
    Harris AL; Grahame-Smith DG; Potter CG; Bunch C
    Clin Sci (Lond); 1981 Feb; 60(2):191-8. PubMed ID: 6940687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine.
    Momparler RL
    Cancer Res; 1974 Aug; 34(8):1775-87. PubMed ID: 4526298
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of acute myeloid leukemia and myelodysplastic syndrome by low dose arabinosyl cytosine.
    Baccarani M; Fasola G; Fanin R; Morassi P; Florean M; Pozzato G; Cavazzini G; Zaccaria A; Guarini L; Lodi L
    Haematologica; 1985; 70(2):160-5. PubMed ID: 3924780
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of tetrahydrouridine on the uptake and metabolism of 1-beta-D-arabinofuranosylcytosine in human normal and leukemic cells.
    Ho DH; Carter CJ; Brown NS; Hester J; McCredie K; Benjamin RS; Freireich EJ; Bodey GP
    Cancer Res; 1980 Jul; 40(7):2444-6. PubMed ID: 6248205
    [No Abstract]   [Full Text] [Related]  

  • 7. Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells.
    Coleman CN; Johns DG; Chabner BA
    Ann N Y Acad Sci; 1975 Aug; 255():247-51. PubMed ID: 171992
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cytokinetic effect of cytosine arabinoside in clinical tests].
    Barlogie B; Büchner T; Asseburg U; Kamanabroo D
    Med Welt; 1974 Sep; 25(39):1532-4. PubMed ID: 4530133
    [No Abstract]   [Full Text] [Related]  

  • 9. 1-beta-D-arabinofuranosylcytosine (ara-C) deamination in human leukemic myeloblasts is not a mechanism of resistance to ara-C therapy.
    Harris AL
    Cancer Res; 1981 Jul; 41(7):2977-9. PubMed ID: 6941850
    [No Abstract]   [Full Text] [Related]  

  • 10. Ara-C metabolism: implications for drug resistance and drug interactions.
    Chabner BA; Hande KR; Drake JC
    Bull Cancer; 1979; 66(1):89-92. PubMed ID: 420952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
    Riva CM; Rustum YM; Preisler HD
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple determinants of antimetabolite action in humans.
    Rustum YM
    Bull Cancer; 1979; 66(1):93-6. PubMed ID: 283838
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

  • 14. Coordinated changes in biochemical patterns: the effect of cytosine arabinoside and methotrexate on leukocytes from patients with acute granulocytic leukemia.
    Roberts D; Hall TC; Rosenthal D
    Cancer Res; 1969 Mar; 29(3):571-8. PubMed ID: 5251290
    [No Abstract]   [Full Text] [Related]  

  • 15. Low dose cytosine arabinoside in adult acute non-lymphoid leukemia.
    Rossi Ferrini P; Ciolli S; Leoni F
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():36-7. PubMed ID: 2713558
    [No Abstract]   [Full Text] [Related]  

  • 16. High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia.
    Nemet D; Labar B; Bogdanić V; Hauptman E; Jaksić B; Minigo H; Sertić D; Mrsić M; Pavletić Z; Kovacević J
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():42-4. PubMed ID: 2697399
    [No Abstract]   [Full Text] [Related]  

  • 17. [Low-dose cytosine arabinoside in the treatment of myeloblastic leukemia].
    Beris P; Chapuis B
    Schweiz Rundsch Med Prax; 1984 Sep; 73(39):1167-8. PubMed ID: 6593780
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of acute myeloid leukemia].
    Obrecht JP
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(2):190-200. PubMed ID: 6208102
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of acute myeloid leukemia in adults with a combination of daunomycin and cytosine-arabinoside].
    Brincker H
    Ugeskr Laeger; 1972 Oct; 134(42):2195-200. PubMed ID: 4563112
    [No Abstract]   [Full Text] [Related]  

  • 20. [Experiences with daunomycin and cytosine arabinoside in the therapy of acute myeloid leukemias].
    Kreiter H; Begemann H; Rastetter J
    Med Klin; 1968 Dec; 63(51):2058-66. PubMed ID: 5255517
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.